X线对比剂的发展及其对计算机断层扫描的潜在影响
本文回顾了X线对比剂的发展历程,指出全球CT检查量每年增长4%、约3亿次,其中约40%为增强扫描;目前静脉用碘对比剂(如碘普罗胺、碘海醇、碘克沙醇)为CT和介入血管造影的 gold standard,低渗与等渗两类效能和安全性相似。未来可能研发不含碘、更适合高X线管电压范围的对比剂,以期在更低辐射剂量下获得等效诊断价值,并为对低渗对比剂有已知反应或甲状腺疾病患者提供替代选择。
要点
- 全球CT检查量每年增长4%、约3亿次,其中约40%为增强扫描。
- 当前CT静脉用碘对比剂为低渗和等渗碘化合物,两类效能与安全性相似。
- 未来可能研发不含碘对比剂,以适配更高X线管电压并降低辐射剂量。
核心结论
- 碘对比剂仍是CT和介入血管造影的 gold standard,低渗与等渗两类效能和安全性相似。
- 未来可能研发不含碘、更适合高X线管电压范围的对比剂,以在更低辐射剂量下提供等效诊断价值。
- 不含碘对比剂还可能为对低渗对比剂有已知反应或甲状腺疾病患者提供替代选择。
- 新对比剂的研发需结合X线及CT的技术进展,新探测器和人工智能算法也将改善图像重建、降低对比剂和辐射剂量。
研究设计与样本
- 本文为综述,回顾过去120年医学影像的持续发展及X线对比剂与CT技术的演变。
临床应用与阅片要点
- 全球CT检查量每年增长4%、约3亿次,其中约40%为增强扫描。
- 当前CT静脉用碘对比剂为低渗和等渗碘化合物,如碘普罗胺、碘海醇或碘克沙醇。
- 低渗与等渗碘对比剂两类效能和安全性相似。
- 未来不含碘对比剂可能为对低渗对比剂有已知反应或甲状腺疾病患者提供替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Over the past 120 years, continuous developments in medical imaging has improved diagnosis and treatment for many diseases and has thereby improved treatment outcome and quality of life of many patients. The number of computed tomography (CT) examinations is today increasing by 4% per year worldwide, for a total of approximately 300 million CT scans per year. About 40% of CT scans are contrast enhanced. Intravenous iodinated contrast media are commonly used for contrast enhancement in CT scans to evaluate diseases and determine treatment response. The current gold standards for intravenous x-ray contrast media in CT or interventional angiography are iodinated low- and iso-osmolar compounds such as iopromide, iohexol, or iodixanol. Both classes have similar and favorable efficacy and safety profiles. Although iodine is biologically inert, iodinated contrast media can cause adverse reactions. In the future, one possibility would be to develop iodine-free contrast media that are better suited to higher x-ray tube voltage ranges, allowing greater flexibility for scanning protocols and thus leading to techniques that can provide equivalent diagnostic value at lower doses of radiation. Iodine-free contrast media would in addition provide an alternative to the market standard that could offer benefits for patients with known reactions to low-osmolality contrast media or thyroid disorders. The development of a new contrast medium, however, needs to be put in context with all upcoming technological advances in x-ray and CT. New detector technologies and artificial intelligence algorithms will in the future also improve the CT image reconstruction enabling the reduction of contrast media and radiation doses.
引用
- Schöckel L, Jost G, Seidensticker P, et al. Developments in X-Ray Contrast Media and the Potential Impact on Computed Tomography. Invest Radiol. 2020. PMID: 32701620. doi:10.1097/RLI.0000000000000696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。